| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dialysis |
Department of Internal Medicine, School of Medicine, University of Missouri–Columbia, Columbia, Missouri
Address correspondence to: Dr. Preethi Yerram, Department of Internal Medicine, MA406, School of Medicine, University of Missouri–Columbia, Columbia, MO 65212. Phone: 573-234-4137; Fax: 573-884-4820; E-mail: yerramp{at}health.missouri.edu
Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis (NSF) is an emerging scleromyxedema-like cutaneous disorder of unknown cause that is seen in patients with renal failure, and the number of reported cases has grown significantly since its first recognition. Recent case reports associated the use of gadolinium (Gd3+)-based contrast agents with the development of NSF. Herein is reported an additional patient who had NSF and had multiple previous exposures to Gd3+-based magnetic resonance imaging studies and had marked improvement in pain and skin changes after a trial of intravenous sodium thiosulfate. Discussed are the possible association of Gd3+-based contrast media with the development of NSF and potential for the use of sodium thiosulfate in the treatment of NSF.
Related Article
Clin. J. Am. Soc. Nephrol. 2007 2: 200-202.
This article has been cited by other articles:
|
|
 |
|
  J. R. Asplin, S. E. Donahue, C. Lindeman, A. Michalenka, K. L. Strutz, and D. A. Bushinsky Thiosulfate Reduces Calcium Phosphate Nephrolithiasis J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1246 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Marckmann, A. H. Nielsen, and J. J. Sloth Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3280 - 3282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Shellock and A. Spinazzi MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis Am. J. Roentgenol., October 1, 2008; 191(4): 1129 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pieringer, S. Schumacher, B. Schmekal, T. Gitter, and G. Biesenbach Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure NDT Plus, June 1, 2008; 1(3): 193 - 194. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mercadal, A. Servais, M. Venditto, N. Renault, C. Isnard-Bagnis, G. Deray, and T. Petitclerc Measuring Plasma Conductivity to Detect Sodium Load in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 743 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kramer, J. Wiskirchen, M. C. Fenchel, A. Seeger, G. Laub, G. Tepe, J. P. Finn, C. D. Claussen, and S. Miller Isotropic High-Spatial-Resolution Contrast-enhanced 3.0-T MR Angiography in Patients Suspected of Having Renal Artery Stenosis Radiology, April 1, 2008; 247(1): 228 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. ISSA, E. D. POGGIO, R. A. FATICA, R. PATEL, P. M. RUGGIERI, and R. J. HEYKA Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 95 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S Peak and A. Sheller Risk Factors for Developing Gadolinium-Induced Nephrogenic Systemic Fibrosis Ann. Pharmacother., September 1, 2007; 41(9): 1481 - 1485. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
